LMC | MANNA RESEARCH NEWS
Latest on what is going on with LMC | MANNA RESEARCH and industry news
hyperCORE International Teams with VirTrial to Become First ‘Virtual Trial Capable’ Site Network in the World| Business Wire
Check out the Business Wire article on the collaboration between VirTrial and hyperCORE, making hyperCORE the first site network to have all sites trained and certified as Virtual Trial Capable. SCOTTSDALE, Ariz.--(BUSINESS WIRE)--VirTrial today announced a...
LOOKING TO OPTIMIZE YOUR SITE’S PERFORMANCE FROM A HR PERSPECTIVE?
Looking to #optimize your site's #performance from a #humanresource perspective? Join LMC Manna Research's president, Karri Venn, for Society for Clinical Research Sites's webinar on "Excelling as a Clinical Research Manager". Use the link below and navigate to...
LMC Manna Research will be at #ADA2019 June 7-11 in San Francisco, CA!
Visit booth #2105 & chat with @karrivenn, President, about diabetes research innovation!Check out our abstracts & presentations in our newsletter: ADA 2019 Newsletter#MakingHealthyEasier #clinicalresearch
First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes
This month, our newest publication is the full report of the Eversense study results. Eversense is the very nifty sensor that is implanted subcutaneously and provides continuous glucose monitoring to your phone for 6 months. Our results were in teenagers...
Announcing the Launch of hyperCORE International
Super Network of highly awarded and experienced Clinical Research Site OrganizationsCOLUMBUS, GA. (PRWEB) APRIL 09, 2019 Announcing the launch of hyperCORE International LLP, a Super Network of highly awarded and experienced Clinical Research...
RESEARCH SPOTLIGHT: Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia
LMC Manna Research's Chief Medical officer Dr. Ronnie Aronson shares our latest publication showcasing our collaborative work with the medications lixisenatide and LixiLan (lixisenatide & lantus combination) over the past decade. This publication is a post-hoc...